Filing Flows › Regeneron Pharmaceuticals (REGN) › Guidance & outlook
Regeneron Pharmaceuticals (REGN) guidance and outlook
Regeneron Pharmaceuticals (REGN) gave its guidance on Oct 30, 2026: Revenue $7.0B for Q4 2026; Revenue +36% for Q4 2026; Revenue +70% for Q4 2026. Regeneron Pharmaceuticals' 10-Q filed Oct 30, 2026 makes 21 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | Q4 2026 | $7.0B | new |
| Revenue | Q4 2026 | +36% | new |
| Revenue | Q4 2026 | +70% | new |
From the earnings release filed Oct 30, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Oct 30, 2026
- • the likelihood and timing of achieving any of our anticipated development milestones referenced in this report;
- • determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates;
- • our ability to meet any of our financial projections or guidance and changes to the assumptions underlying those projections or guidance;
- We will also have the option, on an asset-by-asset basis after completion of certain ongoing clinical trials, to include in the collaboration Sanofi's Phase 2/3 asset lunsekimig, an investigational bispecific Nanobody ® VHH therapy targeting thymic stromal lymphopoietin ("TSLP") and IL-13, and another Sanofi early development product candidate.
- In the event we exercise our option for any such product, we will reimburse Sanofi for certain development costs related to such product.
- We and Alnylam Pharmaceuticals, Inc. are parties to a collaboration to discover, develop, and commercialize RNAi therapeutics for a broad range of diseases by addressing therapeutic disease targets expressed in the eye and central nervous system, in addition to a select number of targets expressed in the liver.
- For each target nominated, we provide Alnylam with a specified amount of funding at program initiation and at lead candidate designation.
- We had the right to select targets under the license and collaboration agreement until April 2026.
- Intellia leads the design of the editing methodology, we lead the design of the targeted viral vector delivery approach, and the parties share costs.
- Each company has the opportunity to lead potential development and commercialization of product candidates for a target, and the company that is not leading development and commercialization will have the option to enter into a co-development and co-commercialization agreement for the target.
- If nex-z is commercialized, Intellia will lead commercialization activities and we will share in 25% of any profits or losses.
- Tessera will lead the initial first-in-human trial, while we will lead subsequent global development and commercialization.
Regeneron Pharmaceuticals' latest quarter
Regeneron Pharmaceuticals, Q3 2026: revenue $5.1B (+36% year over year), operating margin 40.0%, net earnings $1.9B, operating cash flow $1.8B. The chart follows the revenue to costs, profit and cash.
Questions
Did Regeneron Pharmaceuticals raise or lower its guidance?
Regeneron Pharmaceuticals (REGN) gave its guidance on Oct 30, 2026: Revenue $7.0B for Q4 2026; Revenue +36% for Q4 2026; Revenue +70% for Q4 2026.
What does Regeneron Pharmaceuticals expect?
• the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; • determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; • our ability to meet any of our financial projections or guidance and changes to the assumptions underlying those projections or guidance;
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.